Sino Biopharmaceutical Limited (SBP Group) takes the lead again in the "macromolecule patch" field! CPX301, the world's first weight loss dissolvable microneedle patch to receive clearance for a clinical trial from the U.S. Food and Drug Administration (FDA), has entered the clinical development stage.

On August 19, Sino Biopharmaceutical Limited (SBP Group, 1177.HK) announced its 2026 interim results: In the first half of the year, it achieved revenue of RMB 19.44 billion, continuing the double-digit growth trend and reaching a new record high; the adjusted net profit attributable to the parent company from core business reached RMB 3.34 billion, a year-on-year increase of 92.3%, with revenue from innovative medicines and out-licensing becoming the core driver of performance growth. Meanwhile, the Company officially announced the launch of its global brand "SBP Group", articulating its strategy of "Science is where the company starts, Breakthroughs are what it pursues, and Patients are why it does what it does."

On July 1, 2026, on the occasion of the 105th anniversary of the founding of the Communist Party of China, the Hong Kong SAR Government announced the 2026 Honours List, the 29th such list since Hong Kong's return to China. Among the recipients, Ms. Cheng Cheung Ling, one of the founders of Chia Tai Pharmaceutical, founding president of the Hong Kong Chinese Association, President of Chia Tai Pharmaceutical Group, and Vice Chairwoman of the Board of Directors of Sino Biopharmaceutical Limited, was awarded the "Gold Bauhinia Star".

On June 25, E-Healthcare Manager released the "Top 100 Chinese Pharmaceutical Innovation Enterprises" list, with Sino Biopharmaceutical Limited (SBP Group, 1177.HK) once again ranking third.